TD-1607 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Serious Infections Due to Known or Suspected Gram-positive Pathogens
Conditions
Serious Infections Due to Known or Suspected Gram-positive Pathogens
Trial Timeline
Apr 1, 2013 → Oct 1, 2013
NCT ID
NCT01791049About TD-1607 + Placebo
TD-1607 + Placebo is a phase 1 stage product being developed by Theravance Biopharma for Serious Infections Due to Known or Suspected Gram-positive Pathogens. The current trial status is completed. This product is registered under clinical trial identifier NCT01791049. Target conditions include Serious Infections Due to Known or Suspected Gram-positive Pathogens.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01949103 | Phase 1 | Completed |
| NCT01791049 | Phase 1 | Completed |
Competing Products
4 competing products in Serious Infections Due to Known or Suspected Gram-positive Pathogens
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Saizen® A + Saizen® B | Merck | Phase 3 | 77 |
| BAT | Pfizer | Phase 3 | 76 |
| voriconazole IV | Pfizer | Pre-clinical | 22 |
| voriconazole tablet | Pfizer | Pre-clinical | 22 |